SEC Form 4 · accession 0001250853-17-000081
IOVANCE BIOTHERAPEUTICS, INC. · IOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Iain D. Dukes
Director
Period of report
Sep 8, 2017
Accepted (ET)
Sep 12, 2017 · 6:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001425205
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.30 | Sep 8, 2017 | A | 150,000 | A | — | Sep 7, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The options are exercisable and vest quarterly over a three-year period, with 1/12th of the shares having vested on the date of grant. Vesting will accelerate and the entire option will become fully vested upon a significant licensing transaction, a material product acquisition, or a change of control transaction.